☰

Jessica L. Fleming, Ph.D. - Publications

Affiliations: 
2012 Molecular Cellular and Developmental Biology Ohio State University, Columbus, Columbus, OH 
Area:
Cell Biology, Oncology
Tree Info Grants Similar researchers PubMed Report error

34 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Bell EH, Zhang P, Shaw EG, Buckner JC, Barger GR, Bullard DE, Mehta MP, Gilbert MR, Brown PD, Stelzer KJ, McElroy JP, Fleming JL, Timmers CD, Becker AP, Salavaggione AL, et al. Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902983. PMID 32706640 DOI: 10.1200/Jco.19.02983  0.328
2020 Bell EH, Pugh SL, Fisher BJ, Lesser GJ, Macdonald DR, Fleming JL, McElroy JP, Becker AP, Rogers CL, Doyle TJ, Werner-Wasik M, Bahary J, Yu M, D'Souza D, Laack NN, et al. Long-term analysis of the WHO-defined molecular subgroups of high-risk grade II gliomas treated with radiation and temozolomide on NRG Oncology/RTOG 0424. Journal of Clinical Oncology. 38: 2518-2518. DOI: 10.1200/Jco.2020.38.15_Suppl.2518  0.304
2019 Moran NE, Thomas-Ahner JM, Fleming JL, McElroy JP, Mehl R, Grainger EM, Riedl KM, Toland AE, Schwartz SJ, Clinton SK. Single Nucleotide Polymorphisms in β-Carotene Oxygenase 1 are Associated with Plasma Lycopene Responses to a Tomato-Soy Juice Intervention in Men with Prostate Cancer. The Journal of Nutrition. PMID 30801647 DOI: 10.1093/Jn/Nxy304  0.484
2019 Fabian D, Bell EH, McElroy JP, Cui T, Fleming JL, Becker AP, Geurts M, Haque J, Robe PA, Chakravarti A. A preliminary comprehensive molecular-based nomogram for individualized estimation of survival in patients with newly diagnosed glioblastoma utilizing global microRNA expression data. Journal of Clinical Oncology. 37: 2044-2044. DOI: 10.1200/Jco.2019.37.15_Suppl.2044  0.337
2019 Bell EH, Won M, Fleming JL, Becker AP, McElroy JP, Shaw EG, Mehta MP, Brachman DG, Gertler SZ, Murtha AD, Schultz CJ, Johnson DB, Laack NN, Hunter GK, Crocker IR, et al. Updated predictive analysis of the WHO-defined molecular subgroups of low-grade gliomas within the high-risk treatment arms of NRG Oncology/RTOG 9802. Journal of Clinical Oncology. 37: 2002-2002. DOI: 10.1200/Jco.2019.37.15_Suppl.2002  0.303
2019 Sebastian E, Cui T, Bell EH, McElroy J, Johnson B, Gulati PM, Geurts M, Becker AP, Fleming J, Haque SJ, Robe P, Chakravarti A. RDNA-14. RADIATION-INDUCED miR-4516 CONTRIBUTES TO RADIO-RESISTANCE AND PROMOTES AGGRESSIVE PHENOTYPE IN GLIOBLASTOMA Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz175.873  0.306
2018 Beyer SJ, Bell EH, McElroy JP, Fleming JL, Cui T, Becker A, Bassett E, Johnson B, Gulati P, Popp I, Staszewski O, Prinz M, Grosu AL, Haque SJ, Chakravarti A. Oncogenic is differentially regulated in wild-type vs. mutant gliomas. Oncotarget. 9: 37097-37111. PMID 30647847 DOI: 10.18632/Oncotarget.26365  0.337
2018 Cui T, Bell EH, McElroy J, Becker AP, Gulati PM, Geurts M, Mladkova N, Gray A, Liu K, Yang L, Liu Z, Fleming JL, Haque SJ, Barnholtz-Sloan JS, Ligon KL, et al. miR-4516 predicts poor prognosis and functions as a novel oncogene via targeting PTPN14 in human glioblastoma. Oncogene. PMID 30559405 DOI: 10.1038/S41388-018-0601-9  0.356
2018 Bell EH, Zhang P, Fisher BJ, Macdonald DR, McElroy JP, Lesser GJ, Fleming J, Chakraborty AR, Liu Z, Becker AP, Fabian D, Aldape KD, Ashby LS, Werner-Wasik M, Walker EM, et al. Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial. Jama Oncology. PMID 29955793 DOI: 10.1001/Jamaoncol.2018.1977  0.305
2018 Meng W, Bell EH, Singh R, McElroy J, Popp I, Fleming J, Johnson B, Staszewski O, Prinz M, Haque SJ, Grosu A, Chakravarti A. Gene-27. Genome-Wide Dna Methylation Profiling In Grade Ii And Iii Gliomas Reveals A Subset Of Genes With Prognostic Significance Controlled By Promoter Methylation Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.453  0.31
2018 Cui T, Bell EH, Liu K, McElroy J, Geurts M, Gray A, Becker A, Fleming J, Beyer S, Haque J, Robe P, Chakravarti A. CSIG-23. miR-146a PREDICTS BETTER OVERALL SURVIVAL AND ACTS AS A TEMOZOLOMIDE (TMZ) SENSITIZER THROUGH TARGETING MULTIPLE SIGNALING PATHWAYS IN GLIOBLASTOMA Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.189  0.301
2018 Fleming J, Bell EH, Tong Z, Grozdic I, McElroy J, Beyer S, Fabian D, Cui T, Popp I, Staszewski O, Prinz M, Haque SJ, Grosu A, Chakravarti A. CSIG-21. THE ROLE OF miR-219a-2-3p AS A TUMOR SUPPRESSOR IN IDH1/2-WILD-TYPE GRADE II/III GLIOMAS Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.187  0.333
2018 Cui T, Bell EH, McElroy J, Becker A, Gulati P, Geurts M, Mladkova N, Gray A, Liu K, Yang L, Liu Z, Fleming J, Haque SJ, Robe P, Chakravarti A. miR-4516 is a Novel Prognostic Biomarker and Promotes Tumorigenesis via Targeting PTPN14-Mediated Regulation of the Hippo Pathway in Glioblastoma International Journal of Radiation Oncology Biology Physics. 102. DOI: 10.1016/J.Ijrobp.2018.07.656  0.32
2018 Fleming J, McElroy J, Bell EH, Chang SM, Youssef EF, Hunter GK, Yung WA, Howard SP, Bovi JA, Bahary JP, Shih HA, Rabinovitch RA, Chen Y, Zhang P, Chakravarti A. Elevated MGMT Gene Expression is Independently Associated with Worse Overall Survival in NRG Oncology/RTOG 9813: A Phase III Study of Radiation Therapy (RT) and Temozolomide (TMZ) Versus RT and Nitrosourea (NU) in Anaplastic Grade III Glioma International Journal of Radiation Oncology Biology Physics. 102. DOI: 10.1016/J.Ijrobp.2018.06.092  0.317
2017 Beyer S, Fleming J, Meng W, Singh R, Haque SJ, Chakravarti A. The Role of miRNAs in Angiogenesis, Invasion and Metabolism and Their Therapeutic Implications in Gliomas. Cancers. 9. PMID 28698530 DOI: 10.3390/Cancers9070085  0.323
2017 Becker AP, Bell EH, Fleming J, McElroy JP, Fabian D, Beyer S, Salavaggione AL, Graham MK, Heaphy CM, Oehlke O, Staszewski O, Prinz M, Grosu A, Chakravarti A. Comprehensive assessment of ATRX mutation, protein expression, and alternative lengthening of telomeres (ALT) phenotype in grade II and III gliomas. Journal of Clinical Oncology. 35: 2064-2064. DOI: 10.1200/Jco.2017.35.15_Suppl.2064  0.331
2017 Fleming JL, Bell EH, Andrews K, Chakravarti A. Abstract 2527: The role of miR-601 in prostate cancer progression Cancer Research. 77: 2527-2527. DOI: 10.1158/1538-7445.Am2017-2527  0.309
2017 Cui T, Bell EH, McElroy JP, Geurts M, Gulati PM, Becker AP, Fleming J, Yang L, Liu Z, Gray A, Robe P, Chakravarti A. miR-4516 IS A NOVEL PROGNOSTIC MARKER AND PROMOTES PROLIFERATION AND INVASION IN GLIOBLASTOMA Neuro-Oncology. 19: 36-36. DOI: 10.1093/Neuonc/Nox168.139  0.323
2017 Bell EH, Zhang P, Shaw EG, Buckner JC, Barger GR, Coons SW, Bullard DE, Mehta MP, Gilbert MR, Brown PD, Stelzer KJ, Fleming J, McElroy JP, Timmers CD, Becker AP, et al. ACTR-37. PREDICTIVE SIGNIFICANCE OF IDH1/2 MUTATION AND 1p/19q CO-DELETION STATUS IN A POST-HOC ANALYSIS OF NRG ONCOLOGY/RTOG 9802: A PHASE III TRIAL OF RT VS RT + PCV IN HIGH RISK LOW-GRADE GLIOMAS Neuro-Oncology. 19: vi8-vi8. DOI: 10.1093/Neuonc/Nox168.028  0.309
2017 Bell EH, Zhang P, Aldape K, McElroy J, Mehta M, Fleming J, Liu Z, Coons S, Johnson D, Chakravarti A. OS01.7 MGMT promoter methylation status independently predicts progression-free survival in NRG Oncology/RTOG 9802: a phase III trial of RT vs RT + PCV in high-risk low-grade gliomas Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox036.006  0.327
2016 Fleming J, Bell EH, McElroy JP, Fabian D, Beyer S, Salavaggione AL, Öhlke O, Staszewski O, Prinz M, Grosu A, Chakravarti A. Personalized Prognostic microRNA Models for Lower Grade Gliomas. International Journal of Radiation Oncology, Biology, Physics. 96: S91-S92. PMID 27676050 DOI: 10.1016/J.Ijrobp.2016.06.230  0.303
2016 Fleming JL, Bell EH, Andrews K, Chakravarti A. Abstract 1101: The role of miR-601 in prostate cancer progression Cancer Research. 76: 1101-1101. DOI: 10.1158/1538-7445.Am2016-1101  0.357
2016 Bell EH, Zhang P, Shaw EG, Buckner JC, Barger GR, Coons SW, Bullard DE, Mehta MP, Gilbert MR, Brown PD, Stelzer KJ, McElroy JP, Fleming J, Chakraborty A, Becker AP, et al. MPTH-06. 1p/19q CO-DELETION STATUS PREDICTS SURVIVAL OUTCOMES IN NRG ONCOLOGY/RTOG 9802: A PHASE III TRIAL OF RT VS RT + PCV IN HIGH RISK LOW-GRADE GLIOMAS Neuro-Oncology. 18: vi106-vi106. DOI: 10.1093/Neuonc/Now212.444  0.303
2015 Bell EH, Kirste S, Fleming JL, Stegmaier P, Drendel V, Mo X, Ling S, Fabian D, Manring I, Jilg CA, Schultze-Seemann W, McNulty M, Zynger DL, Martin D, White J, et al. A novel miRNA-based predictive model for biochemical failure following post-prostatectomy salvage radiation therapy. Plos One. 10: e0118745. PMID 25760964 DOI: 10.1371/Journal.Pone.0118745  0.307
2015 Bell EH, Kirste S, Fleming JL, Stegmaier P, Drendel V, Mo X, Ling S, Fabian D, Manring I, Jilg CA, Schultze-Seemann W, McNulty M, Zynger DL, Martin D, White J, et al. Abstract 4312: A novel miRNA-based predictive model for biochemical failure following post-prostatectomy salvage radiation therapy Cancer Research. 75: 4312-4312. DOI: 10.1158/1538-7445.Am2015-4312  0.315
2014 Fleming JL, Dworkin AM, Allain DC, Fernandez S, Wei L, Peters SB, Iwenofu OH, Ridd K, Bastian BC, Toland AE. Allele-specific imbalance mapping identifies HDAC9 as a candidate gene for cutaneous squamous cell carcinoma. International Journal of Cancer. Journal International Du Cancer. 134: 244-8. PMID 23784969 DOI: 10.1002/Ijc.28339  0.546
2013 Fleming JL, Gable DL, Samadzadeh-Tarighat S, Cheng L, Yu L, Gillespie JL, Toland AE. Differential expression of miR-1, a putative tumor suppressing microRNA, in cancer resistant and cancer susceptible mice. Peerj. 1: e68. PMID 23646287 DOI: 10.7717/Peerj.68  0.548
2013 Skeeles LE, Fleming JL, Mahler KL, Toland AE. The impact of 3'UTR variants on differential expression of candidate cancer susceptibility genes. Plos One. 8: e58609. PMID 23472213 DOI: 10.1371/Journal.Pone.0058609  0.542
2012 Fleming JL, Phiel CJ, Toland AE. The role for oxidative stress in aberrant DNA methylation in Alzheimer's disease. Current Alzheimer Research. 9: 1077-96. PMID 21605062 DOI: 10.2174/156720512803569000  0.488
2012 Fleming JL, Dworkin AM, Zhang M, Qureshi AA, Allain DC, Fernandez S, Wei L, Peters S, Iwenofu OH, Ridd K, Bastian BC, Han J, Toland AE. Abstract 4857: Allelic-specific imbalance mapping identifiesHDAC9as a candidate susceptibility gene for cutaneous squamous cell carcinoma Cancer Research. 72: 4857-4857. DOI: 10.1158/1538-7445.Am2012-4857  0.568
2012 Gray KM, Dworkin AM, Fleming JL, Toland AE. Abstract 103: DCPS as a cutaneous squamous cell carcinoma susceptibility gene Cancer Research. 72: 103-103. DOI: 10.1158/1538-7445.Am2012-103  0.502
2010 Gable DL, Fleming JL, Toland AE. Abstract 2096: The role of microRNA-1 as a candidate tumor suppressor in cutaneous squamous cell carcinoma Cellular and Molecular Biology. 70: 2096-2096. DOI: 10.1158/1538-7445.Am10-2096  0.537
2008 Mahler KL, Fleming JL, Dworkin AM, Gladman N, Cho HY, Mao JH, Balmain A, Toland AE. Sequence divergence of Mus spretus and Mus musculus across a skin cancer susceptibility locus Bmc Genomics. 9. PMID 19105829 DOI: 10.1186/1471-2164-9-626  0.499
2008 Fleming JL, Huang TH, Toland AE. The role of parental and grandparental epigenetic alterations in familial cancer risk. Cancer Research. 68: 9116-21. PMID 19010880 DOI: 10.1158/0008-5472.Can-08-2184  0.501
Show low-probability matches.